Epidermal Growth Factor Receptor Antagonist class drugs

3 results

  • erbitux

    (cetuximab)
    ImClone LLC
    ERBITUX is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN), recurrent or metastatic SCCHN, K-Ras wild-type metastatic colorectal cancer (mCRC), and BRAF V600E mutation-positive mCRC in combination with specific therapies. It is not for Ras-mutant cancers.

  • portrazza

    (necitumumab)
    Eli Lilly and Company
    PORTRAZZA™ is indicated for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) when used in combination with gemcitabine and cisplatin. It is not approved for non-squamous NSCLC.

  • vectibix

    (panitumumab)
    Amgen Inc
    Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) as first-line therapy with FOLFOX or as monotherapy after prior chemotherapy. It is also approved for KRAS G12C-mutated mCRC in combination with sotorasib in previously treated patients.